MedTrace Logo

Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients

NCT06096064 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-03-24

No results posted yet for this study

Summary

Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels

Conditions

  • Unfractionated Heparin

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-31
Primary Completion
2023-08-21
Completion
2023-08-21

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06096064 on ClinicalTrials.gov